A total of 100 herpes simplex viruses isolated from lesions not responding to acyclovir (ACV) therapy were recovered from 51 patients infected with human immunodeficiency virus. In vitro analysis of these isolates included testing their susceptibility to ACV and determining their thymidine kinase (TK) phenotypes. Of the 100 isolates evaluated, 23 were ACV sensitive and 77 were ACV resistant. Seventy-four of these ACV-resistant isolates were of the TK-deficient or low-TK-producer phenotype and three were of the TK-altered phenotype. The TKs of isolates that represented each of the different autoradiographic phenotypes were further characterized by enzyme kinetics. The ability of selected isolates to cause disease in vivo was evaluated-by using several mouse virulence models. Cutaneous virulence in normal and immunocompromised mice was evaluated, and neurovirulence in normal mice was determined. Latent infections were assayed by the cocultivation of trigeminal ganglia recovered from mice that had survived acute infection. These reactivated viruses were evaluated in vitro and compared with the original infecting isolate. The mechanisms of resistance and pathogenicity of these herpes simplex virus isolates recovered from patients positive for human immunodeficiency virus are similar to those reported for isolates recovered from normal and immunocompromised patients without AIDS.
A total of 100 herpes simplex viruses isolated from lesions not responding to acyclovir (ACV) therapy were recovered from 51 patients infected with human immunodeficiency virus. In vitro analysis of these isolates included testing their susceptibility to ACV and determining their thymidine kinase (TK) phenotypes. Of the 100 isolates evaluated, 23 were ACV sensitive and 77 were ACV resistant. Seventy-four of these ACV-resistant isolates were of the TK-deficient or low-TK-producer phenotype and three were of the TK-altered phenotype. The TKs of isolates that represented each of the different autoradiographic phenotypes were further characterized by enzyme kinetics. The ability of selected isolates to cause disease in vivo was evaluated-by using several mouse virulence models. Cutaneous virulence in normal and immunocompromised mice was evaluated, and neurovirulence in normal mice was determined. Latent infections were assayed by the cocultivation of trigeminal ganglia recovered from mice that had survived acute infection. These reactivated viruses were evaluated in vitro and compared with the original infecting isolate. The mechanisms of resistance and pathogenicity of these herpes simplex virus isolates recovered from patients positive for human immunodeficiency virus are similar to those reported for isolates recovered from normal and immunocompromised patients without AIDS.
The recovery of acyclovir (ACV)-resistant herpes simplex virus (HSV) clinical isolates from patients with normal imnmunity has not been associated with the progression of clinical disease (2, 15, 30) . Normal patients that shed isolates that are ACV resistant in vitro have responded well to continued ACV therapy (31, 46, 47) , and the number of normal patients shedding resistant virus is below 1% of all patients treated (11, 21) , including those on suppressive oral therapy for as long as 1 year (26a) .
However, ACV-resistant HSV has been recovered more frequently from immunocompromised patients such as patients undergoing organ transplantation (4, 32, 50) , cancer patients (35) , patients with congenital abnormalities (3, 13, 45); and patieSts positive for human immunodeficiency virus (HIV) (7, 22) . Infection with ACV-resistant viruses can result in locally progressive mucocutaneous lesions (20, 22, 33, 39) . Although a number of reports have addressed the problem of ACV-resistant HSV in the HIV-positive population, only a small number of patients and their isolates have been described previously (7, 21, 22, 43 Latency. HRS/J mice that survived acute infection were sacrificed 30 days after inoculation, and their trigeminal ganglia were harvested. Explanted ganglia were incubated for 5 days at 370C in supplemented EMEM and then homogenized with a glass homogenizer (Bellco Glass, Inc.). The homogenate was then inoculated on confluent monolayers of Vero cells and checked daily for evidence of viral cytopathic effect. Latency was scored as positive or negative for recoverable virus from explanted ganglia.
The reactivated viruses were evaluated in vitro for susceptibility to ACV, and the viral TKs were analyzed by enzyme kinetics in order to compare them with that of the original infecting isolate.
RESULTS
In vitro drug sensitivities. The in vitro ACV susceptibilities of 100 HSV clinical isolates recovered from 51 patients The in vitro sensitivities of the isolates listed in Table 1 to a variety of TK-activated drugs (ganciclovir and thymidine arabinofuranoside) and drugs that act directly on the viral DNA polymerase (Vidarabine, phosphonoacetic acid, and Foscarnet) were also determined. These isolates remained sensitive to the polymerase inhibitors, and ED Os for them were similar to those for wild-type control viruses. However, ED50s were more than threefold less than those of the polymerase mutant control viruses, phosphonoacetic acidresistant PAAr (27) , and a clinical isolate shown to have a polymerase defect (12) . These drug profiles of these isolates suggest that they are unlikely to have a defect in their polymerase gene function.
The in vitro ED50s for ACV-sensitive and ACV-resistant isolates recovered from patients positive for HIV are similar to those reported for isolates recovered from other patient groups (1, 11, 38) .
In vitro analysis. (45) .
phenotypes. This suggests that the ability of these isolates to viruses were complicated by acute deaths that resulted from produce skin lesions is roughly equivalent in these models.
the initial infection. We were unable to test ganglia from Neurovirulence. The ability of representative isolates to these mice, and we found that mice that received less virus cause lethal infection in BALB/c mice after intracerebral (i.e., a higher dilution) were often uninfected. This is the inoculation is also shown in Table 2 . As previously reported, type of problem encountered with the TK+ isolate VL 10091 differences in pathogenicity of TK+, TKA, and TKD viruses and the TKA isolate VL 11680, and both are listed as are easier to distinguish with neurovirulence models than negative for the reactivation of latent virus. While TKD with cutaneous virulence models (17, 45) . This difference is viruses cannot reactivate (9, 48), low TK producers with illustrated by isolates from patient no. 9. The early isolate diminished amounts of wild-type TK activity can reactivate (VL 10091) was ACV sensitive and TK+, while a later isolate (8, 25) . These results are supported by our latency experi-(VL 10092) was ACV resistant and TKD. The cutaneous ments. virulence PFU/MID50 ratios for hairless HRS/J and athymic The three viruses that were able to establish latent infecmice were 4.9 and 4.6, respectively, for VL 10091 and 5.8 tions (VLs 11575, 11785, and 12247) had wild-type TK and 5.4, respectively, for VL 10092. The neurovirulence activities of 18, 19, and 150%, respectively. All were ACV PFU/LD50 ratios for these same isolates demonstrate a resistant and are either low TK producers (VLs 11575 and significant difference in pathogenicity; the ratio for VL 10091 11785) or TKA (VL 12247). Analyses of the viruses recovwas 1.5 and for VL 10092 was 3.0. This decrease in pathoered from explanted ganglia are shown in Table 3 . The genicity for the TKD viruses agrees with published reports progenies of the cloned isolates (VLs 11785 and 12247) were (24, 45) . The PFU/MID50 ratios are similar to the values similar to the infecting virus. Both VLs 12639 and 12640 are obtained with control viruses of the same TK phenotypes.
ACV resistant and able to phosphorylate TK but not ACV. Latency. While viruses of all three TK phenotypes can
The progeny of the uncloned isolate VL 11575 was ACV establish latency, TKD strains are unable to reactivate from sensitive and able to phosphorylate both TdR and ACV as neurons and cause recurrent disease (9, 24, 48) . The results efficiently as wild-type virus. This results emphasize the of reactivation studies with the trigeminal ganglia from importance of doing in vitro evaluations of the reactivated HRS/J mice that survived snout inoculation are shown in virus rather than assuming that ACV-resistant virus will Table 2 . In our hands, experiments with highly virulent reactivate if ACV-resistant virus is the original infecting DISCUSSION While clinical experience with drug-resistant viruses is limited, the best-studied system of acquired antiviral resistance has been HSV resistant to ACV (4, 13, 32, 45, 50) . The mechanisms of ACV resistance and the in vivo pathogenicity of resistant mutants have been determined with laboratorygenerated ACV-resistant viruses (10, 24, 28) . Mutations in either the virus-encoded TK (TKD, TKA, or low-TK-producer phenotypes) or the viral DNA polymerase can confer resistance to ACV (10, 26, 44) . Viruses of all three phenotypes have been isolated from patients (2, 12, 18, 42) ; however, the predominant ACV-resistant phenotype recovered in the clinic has been TKD (1, 11) . While virus with this phenotype is avirulent in patients with normal immunity (16) , it can cause significant locally progressive disease in immunocompromised patients (4, 6, 13, 20, 22) . The recovery of ACV-resistant virus from immunocompromised patients is not unexpected since these patients usually present with large lesions containing significant amounts of a virus population that may be heterogeneous in terms of susceptibility to ACV (41) . These patients usually receive prolonged and repeated doses of ACV therapy (4, 45) , which in the laboratory is a method of generating ACV-resistant mutants (19, 23) . Since immunocompromised patients cannot depend on their immune system to eliminate ACV-resistant viruses, locally severe herpetic disease can result (3, 4, 45) . The emergence of ACV-resistant isolates in immunocompromised patients appears to correlate primarily with treatment failures, but the appearance of ACV-resistant viruses following recurrent disease has been reported (40, 43) . Therefore, this patient group is at a greater risk for harboring ACVresistant virus and for developing significant disease because of it.
Our results demonstrate that an extremely high percentage of ACV-resistant isolates (77 of 100) can be recovered from patients positive for HIV and not responding to ACV therapy. Virus isolates from this HIV-positive patient population that were originally classified as either ACV sensitive or ACV resistant by their ED50s of ACV have TK phenotypes similar to those of ACV-sensitive or ACV-resistant control viruses. These results confirm that the mechanism of ACV resistance for these viruses is due to a defect in the viral TK. This is the most common type of defect seen in ACVresistant clinical isolates recovered from other patient groups (16 (14, 24) .
The neurovirulence PFU/LD50 ratios resulting from intracerebral inoculation indicate that differences in the pathogenicities of viruses with different TK phenotypes are greater in this model than in models of skin infection. The TKD isolates from patients positive for HIV are less pathogenic than TK+ isolates, which agrees with previous reports with other patient populations (45) . However, there is a recent report of the recovery of a neurovirulent TKD isolate from a patient with AIDS (6) . Since the PFU/LD50 ratios compare favorably with the neurovirulence values generated by our control viruses and with previously reported isolates, we conclude that isolates from patients positive for HIV are not more neuropathogenic than previously reported clinical isolates (18, 24, 45) .
Although all three TK phenotypes can establish latency, TKD viruses cannot reactivate and cause recurrent disease (9, 49) . The amount of TK needed for reactivation by a laboratory-generated TK mutant has been reported to be 10% of wild-type enzyme (8) . In the clinic, ACV-resistant viruses have been isolated from patients with recurrent disease (40, 43) , and when the TK was analyzed, the virus was TKA (40) . Our latency data also indicate that ACVresistant virus can reactivate, but these viruses appear to require a TK that can phosphorylate thymidine. While only rarely have ACV-resistant TKA viruses been recovered from patients (18, 20) , the situation in this patient population may necessitate greater vigilance. This report, which describes 100 HSV isolates recovered from 51 patients positive for HIV, suggests that the emergence of ACV-resistant viruses, in this population, is the result of mechanisms similar to those that have been described for ACV-resistant viruses recovered from other patient groups. Although severe disease can result from ACV-resistant virus in this patient population, such severe disease is presumably the result of the underlying immunodeficiency of the patient and not due to the emergence of mutant HSV strains with enhanced virulence.
